SPOTLIGHT: Novartis: No more deals, no Roche sale

Two questions raised by yesterday's Novartis-Alcon announcement. Is the Swiss drug maker in the market for more deals? And might Novartis offload its one-third stake in Roche to pay for Alcon or some other acquisition. CEO Daniel Vasella (photo) answers both: No. Report | Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.